Sangamo BioSciences | SGMO - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Alaunos Therapeutics USD 1.07M 215K 2023-06
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amgen USD 653M 32M 2025-12
Bayer EUR 675M 87M 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Cipla INR 140.3M 8.5M 2025-12
Compugen USD 954K 116K 2025-09
CSL USD 215M 111M 2025-12
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 188M 21M 2025-12
Grifols EUR 156.07M 31.46M 2025-09
Ionis Pharmaceuticals USD 18M 0 2025-12
J&J USD 18M 290M 2025-09
Karyopharm Therapeutics USD 11.38M 2.43M 2024-09
Merck USD 412M 85M 2025-12
Novartis USD 304M 23M 2025-12
Omeros USD 4.05M 5.16M 2024-09
Pfizer USD 711M 59M 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR -25M 252M 2025-12
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Tectonic Therapeutic USD 12K 276.99M 2025-12
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12